María Sereno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
María Sereno has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Javier de Castro
Hospital Universitario La Paz, Madrid, Spain
6 shared publications Manuel González Barón
La Paz Hospital
4 shared publications- Cristóbal Belda-Iniesta
University Hospital La Paz
3 shared publications Enrique Casado
Infanta Sofía Hospital
3 shared publications- Enrique Casado
Hospital Universitario La Paz, Madrid, Spain
3 shared publications Jaime Feliu
La Paz Hospital
3 shared publications
Latest Publications
- Open Access
- 1 September 2013
- Published by Open Access Publishing London in OA Case Reports
- Vol. 2 (9)
Durable complete response of classic Kaposi s sarcoma of the supraglottis with pegylated liposomal doxorubicin
- 1 September 2013
- Published by Open Access Publishing London in OA Case Reports
- Vol. 2 (9)
Open AccessDurable complete response of classic Kaposi s sarcoma of the supraglottis with pegylated liposomal doxorubicin
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S388-S389
5196 POSTER Relevance of Breast Cancer Subtypes for Magnetic Resonance Imaging (MRI) Response Monitoring Neoadjuvant Chemotherapy (NAC)
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S388-S389
5196 POSTER Relevance of Breast Cancer Subtypes for Magnetic Resonance Imaging (MRI) Response Monitoring Neoadjuvant Chemotherapy (NAC)
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e18033
Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVVA).
E18033 Background: More than 50% of cases of advanced NSCLC are diagnosed in patients (pts) older than 65 years. Furthermore, the majority of pts with NSCLC present at the time of the diagnosis one or more comorbidities. Both subgroups are often under-represented in clinical trials based on perceptions that they do not wish for and/or cannot tolerate active systemic therapy. Methods: AVVA is a multicenter, observational study in pts with advanced NSCLC (stage IIIB noncandidates for radiotherapy or IV) treated with first-line bevacizumab-based regimen. A subanalysis according to age ≥65 years and ≥1 comorbid condition was performed. Preliminary results are presented. Results: A total of 148 pts were evaluated. Median age 57.5 (50-64) years; male 64%; tumor histology: 77% adenocarcinoma, 14% large-cell carcinoma; disease stage IV/IIIB 93%/7%; ECOG 0/1/≥2 37%/56%/7%. 24% of pts were ≥65 years and 64% presented ≥1 comorbid condition at baseline, being the more frequent HTN (19%), dyslipidemia (16%), DM (12%), CVD (7%) and COPD (6%). Commonly used first-line chemotherapy (CT) regimens in combination with bevacizumab were carboplatin doublets in 71% of pts and cisplatin doublets in 26% for a median of 6 cycles. Treatment characteristics and outcomes are specified in the table. The main ≥grade 3 toxicity was DVT in 2.7% of pts. The incidence of ≥ grade 3 AEs of special interest were: haemoptysis <1%, proteinuria <1%, HTN 0%, thromboembolism <1%. DVT (2%) was the only ≥ grade 3 AE reported in elderly pts. In pts with ≥1 comorbidity, DVT (3%), neutropenia (1%) and infection (1%) were the only ≥ grade 3 AEs reported. Conclusions: First-line bevacizumab-based therapy was effective and safe in older pts and pts with at least one comorbid condition. No new safety signals have been indentified and efficacy results match with previously reported data. All patients (n=148) Age ≥65 (n=35) ≥1 comorbid condition (n=95) CT regimen (%) Carboplatin doublets Cisplatin doublets 71 26 68 26 73 25 Median no. of CT cycles 6 6 6 Median no. of bevacizumab cycles 8 6 8 Disease control rate (%) CR PR SD 85.0 1.3 51.3 32.4 85.6 2.9 51.4 31.4 84.1 2.1 52.6 29.5 PFS, months (95% CI) 7.6 (7.2-8.0) 6.6 (5.0-8.2) 7.4 (6.3-8.2)
- 20 May 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (15) , e18033
Clinical outcomes for special populations of patients treated with first-line bevacizumab-based therapy in an observational study (AVVA).
E18033 Background: More than 50% of cases of advanced NSCLC are diagnosed in patients (pts) older than 65 years. Furthermore, the majority of pts with NSCLC present at the time of the diagnosis one or more comorbidities. Both subgroups are often under-represented in clinical trials based on perceptions that they do not wish for and/or cannot tolerate active systemic therapy. Methods: AVVA is a multicenter, observational study in pts with advanced NSCLC (stage IIIB noncandidates for radiotherapy or IV) treated with first-line bevacizumab-based regimen. A subanalysis according to age ≥65 years and ≥1 comorbid condition was performed. Preliminary results are presented. Results: A total of 148 pts were evaluated. Median age 57.5 (50-64) years; male 64%; tumor histology: 77% adenocarcinoma, 14% large-cell carcinoma; disease stage IV/IIIB 93%/7%; ECOG 0/1/≥2 37%/56%/7%. 24% of pts were ≥65 years and 64% presented ≥1 comorbid condition at baseline, being the more frequent HTN (19%), dyslipidemia (16%), DM (12%), CVD (7%) and COPD (6%). Commonly used first-line chemotherapy (CT) regimens in combination with bevacizumab were carboplatin doublets in 71% of pts and cisplatin doublets in 26% for a median of 6 cycles. Treatment characteristics and outcomes are specified in the table. The main ≥grade 3 toxicity was DVT in 2.7% of pts. The incidence of ≥ grade 3 AEs of special interest were: haemoptysis <1%, proteinuria <1%, HTN 0%, thromboembolism <1%. DVT (2%) was the only ≥ grade 3 AE reported in elderly pts. In pts with ≥1 comorbidity, DVT (3%), neutropenia (1%) and infection (1%) were the only ≥ grade 3 AEs reported. Conclusions: First-line bevacizumab-based therapy was effective and safe in older pts and pts with at least one comorbid condition. No new safety signals have been indentified and efficacy results match with previously reported data. All patients (n=148) Age ≥65 (n=35) ≥1 comorbid condition (n=95) CT regimen (%) Carboplatin doublets Cisplatin doublets 71 26 68 26 73 25 Median no. of CT cycles 6 6 6 Median no. of bevacizumab cycles 8 6 8 Disease control rate (%) CR PR SD 85.0 1.3 51.3 32.4 85.6 2.9 51.4 31.4 84.1 2.1 52.6 29.5 PFS, months (95% CI) 7.6 (7.2-8.0) 6.6 (5.0-8.2) 7.4 (6.3-8.2)
- 1 March 2011
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 43 (2) , 181-189
Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer
- 1 March 2011
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 43 (2) , 181-189
Expression Profile as Predictor of Relapse after Adjuvant Treatment in Gastric Cancer
- 11 November 2008
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 15 (1) , 1-10
EPO-R Expression Patterns in Resected Gastric Adenocarcinoma Followed by Adjuvant Chemoradiation Treatment
The primary aim was to determine whether Epo-R immunohistochemical expression is related to disease free survival (DFS) in specimens of GC from patients who underwent adjuvant chemoradiation. Specimens of gastric adenocarcinomas obtained from 44 patients who had undergone curative gastrectomy and adjuvant treatment were investigated immunohistochemically expression of Epo-R. Three patterns for Epo-R staining were defined: Pattern A (secretory cells-like staining), Pattern B (parietal-like staining) and Pattern C (chief-like staining). Median DFS was 38 months (CI 95%: 33–43) and 15 months (IC 95%: 3–27) in the pattern B and C, respectively, but it was not reached in the pattern A (p = 0.06). Our findings suggest that there may be a relationship between Epo-R expression and DFS in the patients with GC resected.
- 11 November 2008
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 15 (1) , 1-10
EPO-R Expression Patterns in Resected Gastric Adenocarcinoma Followed by Adjuvant Chemoradiation Treatment
The primary aim was to determine whether Epo-R immunohistochemical expression is related to disease free survival (DFS) in specimens of GC from patients who underwent adjuvant chemoradiation. Specimens of gastric adenocarcinomas obtained from 44 patients who had undergone curative gastrectomy and adjuvant treatment were investigated immunohistochemically expression of Epo-R. Three patterns for Epo-R staining were defined: Pattern A (secretory cells-like staining), Pattern B (parietal-like staining) and Pattern C (chief-like staining). Median DFS was 38 months (CI 95%: 33–43) and 15 months (IC 95%: 3–27) in the pattern B and C, respectively, but it was not reached in the pattern A (p = 0.06). Our findings suggest that there may be a relationship between Epo-R expression and DFS in the patients with GC resected.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 20704
Use of Internet among cancer patients and their relatives in Spain
20704 Background: The use of Internet as a source of medical information by cancer patients has not been widely studied. Our purpose was to examine the kind of information collected from the web by cancer population as well as the barriers to its use, degree of satisfaction and its effects on the relationship between patient and clinician. Methods: Between June 2006 and September 2007, 109 patients (pts) and 67 relatives were approached in a tertiary hospital and two national health clinics. Ninety-nine patients and 66 relatives completed a structured interview. Information requested included social and demographic data, cancer specific questions and subjective perceptions after the searching the web. Results: 18.2% of pts and 66.7% of cancer relatives used Internet for searching medical information, being the more requested enquiries those concerning general information about the disease (88.2% and 52.9% among pts and relatives respectively) and treatment options (47% of pts and 41.2% of relatives). 77.8% estimated that the search had not helped them in making decisions, though 66.7% considered it had been useful in someway. The main reason for not using the web among pts was their preference to obtain it from physicians (44%) and, secondly, the lack of access to a computer (33.9%); among non users, 45.2% would have desired to have the chance. Regarding the degree of satisfaction, 33% of pts and 46% of relatives felt more confused. Only 11% of patients had discussed the findings with the physician, though from them the 85.7% considered the discussion had been of any help. Conclusions: The use of Internet to obtain cancer related information is not very extended in our country, though many patients and relatives would desire to do so. Besides, between users, the degree of satisfaction achieved is low, and only a reduced subgroup discusses the findings with the physician. Therefore, public health authorities should contemplate the elaboration of newer guidelines in the web aimed at cancer population in an effort to improve the information offered. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 20704
Use of Internet among cancer patients and their relatives in Spain
20704 Background: The use of Internet as a source of medical information by cancer patients has not been widely studied. Our purpose was to examine the kind of information collected from the web by cancer population as well as the barriers to its use, degree of satisfaction and its effects on the relationship between patient and clinician. Methods: Between June 2006 and September 2007, 109 patients (pts) and 67 relatives were approached in a tertiary hospital and two national health clinics. Ninety-nine patients and 66 relatives completed a structured interview. Information requested included social and demographic data, cancer specific questions and subjective perceptions after the searching the web. Results: 18.2% of pts and 66.7% of cancer relatives used Internet for searching medical information, being the more requested enquiries those concerning general information about the disease (88.2% and 52.9% among pts and relatives respectively) and treatment options (47% of pts and 41.2% of relatives). 77.8% estimated that the search had not helped them in making decisions, though 66.7% considered it had been useful in someway. The main reason for not using the web among pts was their preference to obtain it from physicians (44%) and, secondly, the lack of access to a computer (33.9%); among non users, 45.2% would have desired to have the chance. Regarding the degree of satisfaction, 33% of pts and 46% of relatives felt more confused. Only 11% of patients had discussed the findings with the physician, though from them the 85.7% considered the discussion had been of any help. Conclusions: The use of Internet to obtain cancer related information is not very extended in our country, though many patients and relatives would desire to do so. Besides, between users, the degree of satisfaction achieved is low, and only a reduced subgroup discusses the findings with the physician. Therefore, public health authorities should contemplate the elaboration of newer guidelines in the web aimed at cancer population in an effort to improve the information offered. No significant financial relationships to disclose.
- 1 January 2008
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 10 (1) , 35-46
Cardiac toxicity: old and new issues in anti-cancer drugs
Although rare, cardiotoxicity is a significant complication of cancer treatment. The incidence and severity of cardiovascular side effects are dependent on the type of drugs used, dose and schedule employed, and age of patients, as well as the presence of coexisting cardiac diseases and previous mediastinal irradition. Classically, anthracyclines are among one of the most active agents in oncology, but their use is often hampered by their cumulative dose-limiting cardiotoxicity. In the past decade, combination therapy with new drugs such as taxanes of anti-EGFR, and Her-2 therapy as a single agent have also resulted in unexpected cardiotoxicity. Cardiac damage can be secondary to an alteration of cardiac rhythm, changes in blood pressure and ischaemia, and can also alter the ability of the heart to contract and/or relax. The clinical spectrum of these toxicities can range from subclinical abnormalities to being catastrophic, life-threatening and sometimes fatal. Knowledge of this toxicity can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient. In this work we present an exhaustive review of the cardiovascular side effects associated to new anticancer drugs, from new formulations of anthracyclines to tyrosine kinase inhibitors and monoclonal antibodies.
- 1 January 2008
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 10 (1) , 35-46
Cardiac toxicity: old and new issues in anti-cancer drugs
Although rare, cardiotoxicity is a significant complication of cancer treatment. The incidence and severity of cardiovascular side effects are dependent on the type of drugs used, dose and schedule employed, and age of patients, as well as the presence of coexisting cardiac diseases and previous mediastinal irradition. Classically, anthracyclines are among one of the most active agents in oncology, but their use is often hampered by their cumulative dose-limiting cardiotoxicity. In the past decade, combination therapy with new drugs such as taxanes of anti-EGFR, and Her-2 therapy as a single agent have also resulted in unexpected cardiotoxicity. Cardiac damage can be secondary to an alteration of cardiac rhythm, changes in blood pressure and ischaemia, and can also alter the ability of the heart to contract and/or relax. The clinical spectrum of these toxicities can range from subclinical abnormalities to being catastrophic, life-threatening and sometimes fatal. Knowledge of this toxicity can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient. In this work we present an exhaustive review of the cardiovascular side effects associated to new anticancer drugs, from new formulations of anthracyclines to tyrosine kinase inhibitors and monoclonal antibodies.
- 11 January 2007
- Vol. 50 (4) , 285-92
Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.
Different authors have investigated the immunohistochemical expression of some proteins in the adenocarcinoma of the stomach, including cell cycle regulators proteins like p53 and Bcl-2; growth factors (c-erb-B2 and EPO-R); angiogenesis-related markers such as COX-2 and cellular adhesion molecules (beta-catenin and E-cadherin). While these proteins have been studied in gastric adenocarcinoma, their immunophenotyping in non tumoral gastric mucous membrane remains unexplored. In the present study, we investigated the expression, function and behavior of these proteins in normal gastric mucous membrane to contribute to gain further knowledge on the significance of their loss or overexpression in malignant gastric tumors.
- 11 January 2007
- Vol. 50 (4) , 285-92
Immunohistochemical expression of p53, Bcl-2, COX-2, C-erb-B2, EPO-R, beta-catenin, and E-cadherin in non tumoral gastric mucous membrane.
Different authors have investigated the immunohistochemical expression of some proteins in the adenocarcinoma of the stomach, including cell cycle regulators proteins like p53 and Bcl-2; growth factors (c-erb-B2 and EPO-R); angiogenesis-related markers such as COX-2 and cellular adhesion molecules (beta-catenin and E-cadherin). While these proteins have been studied in gastric adenocarcinoma, their immunophenotyping in non tumoral gastric mucous membrane remains unexplored. In the present study, we investigated the expression, function and behavior of these proteins in normal gastric mucous membrane to contribute to gain further knowledge on the significance of their loss or overexpression in malignant gastric tumors.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 9697
A inmunohistochemical expression profile as prognostic factor in locally advanced gastric cancer relapse
9697 Background: Surgical resection of gastric adenocarcinoma is curative in less than 40% of patients, so local regional or distance recurrence occurs in 40–60% of cases. New prognostic and predictive factors are needed to define the best candidates to receive adjuvant treatment. Methods: Expression of Bcl-2,p53,Cox-2,HER-2,Epo-R,β-catenin and E-cadherin proteins were evaluated by immunohistochemistry on 45 selected parafin-embedded gastrectomy specimens of gastric adenocarcinomas using an indirect inmunoperoxidase technique. All patients had received adjuvant treatment according to McDonald’s protocol(NEJM,2001;345:725). Inmunohistochemical staining for these proteins was correlated with clinico-pathological features: stage, histological subtype, differentiation, macroscopic appearance and recurrence. Results: Correlation with clinico-pathological features:p53 overexpression was higher in III-IVA vs IB-II (81%vs53%,p<0.049).In the intestinal type vs diffuse type we found p53 (91%vs51%,p<0.002) and Cox-2 (86%vs66%,p<0.001) overexpression, strong staining for Epo-R (95%vs72%,p <0.04)and lack of staining for expression of HER-2 (95%vs45%,p<0.0001). Normal inmunohistochemical expression of β-catenin occurred in 95%(p<0,02)of protruding gastric carcinoma(typeI in Borman classification)and in 91% intestinal subtype,as seen with E-cadherin.None expression changes were observed between differentiated vs undifferentiated gastric cancer. Recurrence expression profile:45 cases were studied and we found 15 recurrences(33.3%)at 2 years of follow-up.The inmunohistochemical profile was similar in 9 of the 15 cases(60%):Lack of staining for Bcl-2 and HER-2,normal expression of β-catenin and E-cadherin and overexpression of for p53,Cox-2 and Epo-R.Conversely, this inmunophenotype appeared only in 3 of 30(10%) cases that didn’t relapse after 2 years of follow-up,(p<0.01). Conclusions: These findings suggest that it could be possible to identify a pattern expression of p53, Bcl-2, Cox-2,HER-2,Epo-R,β-catenin and E-cadherin proteins to select gastric cancer resected patients with a worse prognosis who could benefit from an adjuvant treatment. No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 9697
A inmunohistochemical expression profile as prognostic factor in locally advanced gastric cancer relapse
9697 Background: Surgical resection of gastric adenocarcinoma is curative in less than 40% of patients, so local regional or distance recurrence occurs in 40–60% of cases. New prognostic and predictive factors are needed to define the best candidates to receive adjuvant treatment. Methods: Expression of Bcl-2,p53,Cox-2,HER-2,Epo-R,β-catenin and E-cadherin proteins were evaluated by immunohistochemistry on 45 selected parafin-embedded gastrectomy specimens of gastric adenocarcinomas using an indirect inmunoperoxidase technique. All patients had received adjuvant treatment according to McDonald’s protocol(NEJM,2001;345:725). Inmunohistochemical staining for these proteins was correlated with clinico-pathological features: stage, histological subtype, differentiation, macroscopic appearance and recurrence. Results: Correlation with clinico-pathological features:p53 overexpression was higher in III-IVA vs IB-II (81%vs53%,p<0.049).In the intestinal type vs diffuse type we found p53 (91%vs51%,p<0.002) and Cox-2 (86%vs66%,p<0.001) overexpression, strong staining for Epo-R (95%vs72%,p <0.04)and lack of staining for expression of HER-2 (95%vs45%,p<0.0001). Normal inmunohistochemical expression of β-catenin occurred in 95%(p<0,02)of protruding gastric carcinoma(typeI in Borman classification)and in 91% intestinal subtype,as seen with E-cadherin.None expression changes were observed between differentiated vs undifferentiated gastric cancer. Recurrence expression profile:45 cases were studied and we found 15 recurrences(33.3%)at 2 years of follow-up.The inmunohistochemical profile was similar in 9 of the 15 cases(60%):Lack of staining for Bcl-2 and HER-2,normal expression of β-catenin and E-cadherin and overexpression of for p53,Cox-2 and Epo-R.Conversely, this inmunophenotype appeared only in 3 of 30(10%) cases that didn’t relapse after 2 years of follow-up,(p<0.01). Conclusions: These findings suggest that it could be possible to identify a pattern expression of p53, Bcl-2, Cox-2,HER-2,Epo-R,β-catenin and E-cadherin proteins to select gastric cancer resected patients with a worse prognosis who could benefit from an adjuvant treatment. No significant financial relationships to disclose.
- 1 January 2005
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 7 (1) , 29-30
Subacute dementia as presenting feature of carcinomatous leptomeningeal metastases
- 1 January 2005
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 7 (1) , 29-30
Subacute dementia as presenting feature of carcinomatous leptomeningeal metastases